Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Èíôîðìàöèÿ è êîììåð÷åñêàÿ ðåêëàìà > Ëåêàðñòâåííûå ïðåïàðàòû

Ëåêàðñòâåííûå ïðåïàðàòû Ðàçìåùåíèå ðåêëàìû ïëàòíîå. Ïèøèòå.

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1  
Ñòàðûé 08.07.2011, 01:18
cooler cooler âíå ôîðóìà
Ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 16.08.2009
Ãîðîä: Îäåññà
Ñîîáùåíèé: 122
Ñêàçàë(à) ñïàñèáî: 408
Ïîáëàãîäàðèëè 3 ðàç(à) çà 2 ñîîáùåíèé
cooler *
Âèáóðêîë

Çäðàâñòâóéòå, óâàæàåìûå ñïåöèàëèñòû!
Òî, ÷òî ñâå÷è Âèáóðêîë íå ÿâëÿþòñÿ ïðåïàðàòîì ñ äîêàçàííîé ýôôåêòèâíîñòüþ, ìíå ïîíÿòíî. Îá ýòîì íà ôîðóìå ñêàçàíî ìíîãî ðàç. Ïðîáëåìà â òîì, ÷òî ìîÿ ñóïðóãà, íàõîäÿñü â ñãîâîðå ñ íàøèì ïåäèàòðîì, èíîãäà ÿâíî, à èíîãäà è òàéíî çàïèõèâàþò åãî â ðåáåíêà ïî ðàçíûì ïðè÷èíàì: ïîäíÿëàñü òåìïåðàòóðà, íå òàê ïóêàåò è ò. ä. Îáå óâåðåíû, ÷òî ïîìîãàåò. Õîòÿ, ïðèçíàþñü, ÿ òîæå òàê ñ÷èòàë, ïîêà íå íàáðåë íà ýòîò ôîðóì.
Ðàçóìååòñÿ, ñàìîå ãëàâíîå, ÷òî âîëíóåò ìåíÿ â äàííîì âîïðîñå - áåçîïàñíîñòü.  ïîèñêàõ èñòèíû ÿ ðåøèë ïîñåòèòü Ïàáìåä, è íàøåë òàì [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ïðî Âèáóðêîë. Íàñêîëüêî ÿ ïîíÿë, Áåëüãèéñêèå èññëåäîâàòåëè âûÿñíèëè, ÷òî Âèáóðêîë ÷åì-òî íåìíîæêî ëó÷øå ïàðàöåòàìîëà (â ïîäðîáíîñòÿõ ÿ íå ðàçîáðàëñÿ), íî èññëåäîâàíèÿ âðîäå äàëåêè îò èäåàëà.
Íåìíîãî ïîãóãëèâ, òàêæå íàøåë èíôîðìàöèþ, ÷òî â Ãåðìàíèè îí òîæå ïðîäàåòñÿ, è ïðèìåíÿåòñÿ ìíîãî ëåò.

Ñàìûé âàæíûé âîïðîñ: ìîæíî ëè ñ÷èòàòü ýòè ñâå÷è áåçîïàñíûìè? Áûëè ëè çàðåãèñòðèðîâàíû ñåðüåçíûå ïîáî÷íûå ýôôåêòû?

Äðóãèå âîïðîñû, èç ëþáîïûòñòâà: â Ãåðìàíèè, Áåëüãèè è äðóãèõ öèâèëèçîâàííûõ åâðîïåéñêèõ ñòðàíàõ âðà÷è àêòèâíî íàçíà÷àþò ýòîò ïðåïàðàò? Íà ÷òî îíè îïèðàþòñÿ? Ìîæåò, ó íèõ ñâîé àíàëîã Ïàáìåäà è ñâîè ìåòîäû ïðîâåäåíèÿ èñïûòàíèé?
Îòâåòèòü ñ öèòèðîâàíèåì
  #2  
Ñòàðûé 08.07.2011, 07:55
Àâàòàð äëÿ Tuu-Tikki
Tuu-Tikki Tuu-Tikki âíå ôîðóìà
Òåðàïåâò äëÿ áåðåìåííûõ
      
 
Ðåãèñòðàöèÿ: 08.02.2006
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 4,804
Ñêàçàë(à) ñïàñèáî: 10
Ïîáëàãîäàðèëè 2,452 ðàç(à) çà 2,214 ñîîáùåíèé
Tuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Íîðìàëüíûõ èñïûòàíèé åãî ýôôåêòèâíîñòè è áåçîïàñíîñòè íå ïðîâîäèëîñü. Äàííûõ î ñåðüåçíûõ ïîáî÷íûõ ýôôåêòàõ íàéòè íå óäàëîñü, âîçìîæíî ýòîò "ïðåïàðàò" ÿâëÿåòñÿ áåçîïàñíûì.
Ãîìåîïàòèÿ äåéñòâèòåëüíî íåæíî ëþáèìà â Åâðîïå, îñîáåííî â Ãåðìàíèè, êîòîðàÿ ÿâëÿåòñÿ ðîäèíîé ãîìåîïàòèè.
Ïîëíîöåííûå êëèíè÷åñêèå èñïûòàíèÿ ãîìåîïàòè÷åñêèõ ïðåïàðàòîâ íåâîçìîæíî ïðîâåñòè ïî îïðåäåëåíèþ, ïîýòîìó ñòîðîííèêè ýòîãî ìåòîäà ëå÷åíèÿ âïîëíå óäîâëåòâîðÿþòñÿ ðåçóëüòàòàìè èññëåäîâàíèé, ïðîâåäåííûõ ïî ñèëüíî "îáëåã÷åííîé" ñõåìå.
__________________
Ñ óâàæåíèåì, Îëüãà Èâàíîâíà Áåëîâåæåö
Îòâåòèòü ñ öèòèðîâàíèåì
  #3  
Ñòàðûé 09.07.2011, 01:30
cooler cooler âíå ôîðóìà
Ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 16.08.2009
Ãîðîä: Îäåññà
Ñîîáùåíèé: 122
Ñêàçàë(à) ñïàñèáî: 408
Ïîáëàãîäàðèëè 3 ðàç(à) çà 2 ñîîáùåíèé
cooler *
Ñïàñèáî, óñïîêîèëè...
Îòâåòèòü ñ öèòèðîâàíèåì
  #4  
Ñòàðûé 09.07.2011, 05:45
Lobanoff Lobanoff âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 11.04.2011
Ãîðîä: Èðêóòñê
Ñîîáùåíèé: 3
Lobanoff *
Åñëè ó÷åñòü, ÷òî Âèáóðêîë - ýòî íå ãîìåîïàòèÿ, à ãîìîòîêñèêîëîãèÿ, òî îáñóæäåíèå íåèçâåñòíîãî ïðåäìåòà áóäåò îñîáåííî äîñòîâåðíûì.
Îòâåòèòü ñ öèòèðîâàíèåì
  #5  
Ñòàðûé 09.07.2011, 10:46
Àâàòàð äëÿ Tuu-Tikki
Tuu-Tikki Tuu-Tikki âíå ôîðóìà
Òåðàïåâò äëÿ áåðåìåííûõ
      
 
Ðåãèñòðàöèÿ: 08.02.2006
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 4,804
Ñêàçàë(à) ñïàñèáî: 10
Ïîáëàãîäàðèëè 2,452 ðàç(à) çà 2,214 ñîîáùåíèé
Tuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ðàçíèöà ìåæäó ãîìåîïàòèåé è ãîìîòîêñèêîëîãèåé â äàííîì ñëó÷àå íåïðèíöèïèàëüíà. È òàì, è òàì èñïîëüçóþòñÿ ïðåïàðàòû ñ íåäîêàçàííîé ýôôåêòèâíîñòüþ.
__________________
Ñ óâàæåíèåì, Îëüãà Èâàíîâíà Áåëîâåæåö
Îòâåòèòü ñ öèòèðîâàíèåì
  #6  
Ñòàðûé 09.07.2011, 11:20
cooler cooler âíå ôîðóìà
Ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 16.08.2009
Ãîðîä: Îäåññà
Ñîîáùåíèé: 122
Ñêàçàë(à) ñïàñèáî: 408
Ïîáëàãîäàðèëè 3 ðàç(à) çà 2 ñîîáùåíèé
cooler *
Äëÿ ñïåöèàëèñòîâ, âîçìîæíî, ðàçíèöû è íåò. Íî äóìàþ, åñëè áû ïðè íàçíà÷åíèè ãîâîðèëîñü, ÷òî ýòî ãîìîòîêñèêîëîãè÷åñêèé ïðåïàðàò, íàìíîãî ìåíüøå áûëî áû æåëàíèÿ ó ðîäèòåëåé çàïèõèâàòü åãî â ðåáåíêà. À êîãäà ãîâîðÿò, ÷òî ïðåïàðàò ãîìåîïàòè÷åñêèé, äëÿ íåïîäãîòîâëåííîãî ïàöèåíòà (ÿ ïî ñåáå ñóæó) ýòî ÿâëÿåòñÿ ñèíîíèìîì "áåçâðåäíûé, íàòóðàëüíûé"

Ïîéäó æåíå ðàññêàæó, ïîñìîòðþ íà ðåàêöèþ... Íàøåìó äâóõìåñÿ÷íîìó ìàëûøó êàê ðàç ïåäèàòð ñíîâà åãî íàçíà÷èëà...
Îòâåòèòü ñ öèòèðîâàíèåì
  #7  
Ñòàðûé 13.07.2011, 04:39
Lobanoff Lobanoff âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 11.04.2011
Ãîðîä: Èðêóòñê
Ñîîáùåíèé: 3
Lobanoff *
Öèòàòà:
Ñîîáùåíèå îò Tuu-Tikki Ïîñìîòðåòü ñîîáùåíèå
Ðàçíèöà ìåæäó ãîìåîïàòèåé è ãîìîòîêñèêîëîãèåé â äàííîì ñëó÷àå íåïðèíöèïèàëüíà. È òàì, è òàì èñïîëüçóþòñÿ ïðåïàðàòû ñ íåäîêàçàííîé ýôôåêòèâíîñòüþ.
 äàííîì êîíòåêñòå ïðèíöèïèàëüíà ðàçíèöà òåõíîëîãèé ïðèãîòîâëåíèé è ôèëîñîôèè íàçíà÷åíèÿ.  ãîìîòîêñèêîëîãèè ïðèìåíÿþòñÿ ïîòåíöèðîâàííûå àëëîïàòè÷åñêèå ïðåïàðàòû, âèòàìèíû, ôåðìåíòû, îðãàíû æèâîòíûõ è êëàññè÷åñêèå ãîìåîïàòè÷åñêèå ïðåïàðàòû.  ãîìîòîêñèêîëîãèè ìîæíî ãîâîðèòü è î äîçàõ, ò. ê. ðàçâåäåíèÿ, ÷àùå âñåãî, íå âûõîäÿò çà ïðåäåëû ÷èñëà Àâîãàäðî. Ôèëîñîôèÿ íàçíà÷åíèÿ îñíîâûâàåòñÿ íà èçâåñòíîé îáû÷íûì âðà÷àì íîçîëîãèè, à íå íà ãîìåîïàòè÷åñêîì ïàòîãåíåçå.
Ãîìîòîêñèêîëîãèÿ øèðîêî ïðèìåíÿåòñÿ âî ìíîãèõ åâðîïåéñêèõ ñòðàíàõ. Íàñ÷åò äîêàçàòåëüñòâ - íóæíî ïðîñòî ïîèñêàòü â ëþáèìûõ PubMed èëè Ìåäëàéíå.
Îòâåòèòü ñ öèòèðîâàíèåì
  #8  
Ñòàðûé 13.07.2011, 06:25
BBC BBC âíå ôîðóìà
ìîäåðàòîð ôîðóìà
      
 
Ðåãèñòðàöèÿ: 15.08.2005
Ãîðîä: Ñàíêò-Ïåòåðáóðã
Ñîîáùåíèé: 31,518
Ïîáëàãîäàðèëè 4,832 ðàç(à) çà 3,086 ñîîáùåíèé
BBC ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåBBC ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåBBC ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåBBC ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåBBC ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåBBC ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåBBC ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåBBC ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåBBC ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåBBC ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåBBC ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Òî åñòü 2 âèäà øàðëàòàíñòâà ðàçëè÷àþòñÿ ñòåïåíüþ ôèëîñîôè÷íîñòè è ÷èñëîì Àâîãàäðî?
__________________
Ñ óâàæåíèåì,
Âàëåðèé Âàëåðüåâè÷ Ñàìîéëåíêî
Îòâåòèòü ñ öèòèðîâàíèåì
  #9  
Ñòàðûé 13.07.2011, 11:09
Àâàòàð äëÿ Tuu-Tikki
Tuu-Tikki Tuu-Tikki âíå ôîðóìà
Òåðàïåâò äëÿ áåðåìåííûõ
      
 
Ðåãèñòðàöèÿ: 08.02.2006
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 4,804
Ñêàçàë(à) ñïàñèáî: 10
Ïîáëàãîäàðèëè 2,452 ðàç(à) çà 2,214 ñîîáùåíèé
Tuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ïðåäñòàâëåíèÿ î ïàòîãåíåçå çàáîëåâàíèé â ãîìîòîêñèêîëîãèè ôàíòàñòè÷íû, íå ìåíåå ôàíòàñòè÷íî ïðåäñòàâëåíèå î íîçîäàõ èëè ïîòåíöèðîâàíèè.
Èñòî÷íèêè, â êîòîðûõ ïóáëèêóþòñÿ äàííûå ïî âèáóðêîëó, óâû, íå âíóøàþò.
__________________
Ñ óâàæåíèåì, Îëüãà Èâàíîâíà Áåëîâåæåö
Îòâåòèòü ñ öèòèðîâàíèåì
  #10  
Ñòàðûé 16.07.2011, 05:40
Lobanoff Lobanoff âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 11.04.2011
Ãîðîä: Èðêóòñê
Ñîîáùåíèé: 3
Lobanoff *
Öèòàòà:
Ñîîáùåíèå îò BBC Ïîñìîòðåòü ñîîáùåíèå
Òî åñòü 2 âèäà øàðëàòàíñòâà ðàçëè÷àþòñÿ ñòåïåíüþ ôèëîñîôè÷íîñòè è ÷èñëîì Àâîãàäðî?
Ïî÷åìó æå? Åñòü è ïî ñòåïåíè ôèíàíñîâûõ âëîæåíèé, íàïðèìåð, ëå÷åíèå çäîðîâûõ ãåëèêîáàêòåðîâ è õëàìèäèé!
Îòâåòèòü ñ öèòèðîâàíèåì
  #11  
Ñòàðûé 16.07.2011, 05:46
Lobanoff Lobanoff âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 11.04.2011
Ãîðîä: Èðêóòñê
Ñîîáùåíèé: 3
Lobanoff *
Öèòàòà:
Ñîîáùåíèå îò Tuu-Tikki Ïîñìîòðåòü ñîîáùåíèå
Ïðåäñòàâëåíèÿ î ïàòîãåíåçå çàáîëåâàíèé â ãîìîòîêñèêîëîãèè ôàíòàñòè÷íû, íå ìåíåå ôàíòàñòè÷íî ïðåäñòàâëåíèå î íîçîäàõ èëè ïîòåíöèðîâàíèè.
Èñòî÷íèêè, â êîòîðûõ ïóáëèêóþòñÿ äàííûå ïî âèáóðêîëó, óâû, íå âíóøàþò.
 ìåäèöèíå ìíîãîå ôàíòàñòè÷íî, äî ñèõ ïîð èäåò ñïîð, ÷òî ýòî - íàóêà èëè èñêóññòâî?
Ó÷èòûâàÿ áåçâðåäíîñòü ýòèõ ôàíòàçèé, äîêàçàííûé ýôôåêò îò äåéñòâèÿ ïëàöåáî íà óðîâíå îêîëî 30 ïðîöåíòîâ â ïîïóëÿöèè, âïîëíå ïðèåìëåìûé ìåòîä ëå÷åíèÿ, êîãäà ìîæíî îáîéòèñü áåç ëå÷åíèÿ, îãðàäèâ áîëüíîãî îò îïàñíîé "òÿæåëîé" ôàðìàêîòåðàïèè.
Îòâåòèòü ñ öèòèðîâàíèåì
  #12  
Ñòàðûé 16.07.2011, 06:38
Àâàòàð äëÿ easl
easl easl âíå ôîðóìà
Âðà÷-èíôåêöèîíèñò
      
 
Ðåãèñòðàöèÿ: 05.02.2008
Ãîðîä: Áàêó
Ñîîáùåíèé: 18,438
Ïîáëàãîäàðèëè 5,211 ðàç(à) çà 4,962 ñîîáùåíèé
easl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Lobanoff Ïîñìîòðåòü ñîîáùåíèå
Ïî÷åìó æå? Åñòü è ïî ñòåïåíè ôèíàíñîâûõ âëîæåíèé, íàïðèìåð, ëå÷åíèå çäîðîâûõ ãåëèêîáàêòåðîâ è õëàìèäèé!
Äà-äà! ×åì çäîðîâåå ãeëèêîáàêòåð è õëàìèäèÿ, òåì áîëüøå ôèíàíñîâûõ âëîæåíèé!
Èëè âû î äðóãîì?
__________________
Ñ óâàæåíèåì, Þñèô Àëõàçîâ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #13  
Ñòàðûé 17.07.2011, 15:33
Lobanoff Lobanoff âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 11.04.2011
Ãîðîä: Èðêóòñê
Ñîîáùåíèé: 3
Lobanoff *
Öèòàòà:
Ñîîáùåíèå îò easl Ïîñìîòðåòü ñîîáùåíèå
Äà-äà! ×åì çäîðîâåå ãeëèêîáàêòåð è õëàìèäèÿ, òåì áîëüøå ôèíàíñîâûõ âëîæåíèé!
Èëè âû î äðóãîì?
Åñëè áóäåò ðåôåðåíäóì ïî ãåëèêîáàêòåðó, áóäó ãîëîñîâàòü çà âêëþ÷åíèå åãî â ãðóïïó ÎÎÈ, è êàê èíôåêöèîíèñòîâ ñ ýòèì ïðîéäîõîé îáîøëè?
Ïîñìîòðåë ðåçþìå ïî îáçîðó èññëåäîâàíèé â ãîìîòîêñèêîëîãèè.
J Clin Pharmacol. 2004 Jul;60(5):299-306. Epub 2004 Jun 9.
Homotoxicology--a review of randomised clinical trials.
Ernst E, Schmidt K.
Source
Complementary Medicine, Peninsula Medical School, Universities of Exeter and Plymouth, 25 Victoria Park Road, Exeter EX2 4NT, UK. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Abstract
AIM:
Homotoxicology is a form of therapy that uses homoeopathically diluted remedies with a view of eliminating toxins from the body. It is not a therapeutic method based on accepted scientific principles or biological plausibility. Yet numerous clinical studies have claimed efficacy. The aim of this systematic review is to summarise and critically evaluate the evidence from rigorous clinical trials of this form of therapy.
METHODS:
Seven electronic databases were searched for all studies of homotoxicological medicines for any human condition. To be included, trials had to be randomised and placebo-controlled. Data from such studies were validated and extracted according to pre-defined criteria. Their methodological quality was formally assessed using the Jadad score. Key data of all included trials were tabulated and summarised in narrative form.
RESULTS:
Seven trials met our inclusion criteria. Their Jadad scores indicated mostly a high methodological standard. The trials tested the efficacy of seven different medicines for seven different indications. The results were positive in all but one study. Important flaws were found in all trials. These render the results of the primary studies less reliable than their high Jadad scores might suggest.
CONCLUSION:
Despite mostly positive findings and high ratings on the Jadad score, the placebo-controlled, randomised clinical trials of homotoxicology fail to demonstrate the efficacy of this therapeutic approach.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Ðåçóëüòàòû íå óòåøèòåëüíû.
Âîò ïî÷òè ñîâñåì ñâåæåå èññëåäîâàíèå.
Altern Ther Health Med. 2010 Jan-Feb;16(1):54-9.
A series of case reports: clinical evaluation of a complex homeopathic injection therapy in the management of pain in patients after breast cancer treatment.
Orellana Alvarellos G, Ruiz de Viñaspre Alvear P, Kaszkin-Bettag M.
Source
Center of Obstetrics and Gynecology, Ginesia SA, Providencia, Santiago de Chile, Chile.
Abstract
OBJECTIVE:
In breast cancer patients, posttreatment pain often appears after several months and strongly impairs health-related quality of life. Conventional methods of pain reduction are often ineffective. Injection therapy with Traumeel (Heel GmbH, Baden-Baden, Germany), a medication with analgesic properties used in homotoxicology for treatment of the pain associated with trauma as well as a mediator of inflammation, was proposed as an innovative approach for pain relief after breast cancer treatment.
DESIGN:
Nine patients, still suffering from a high level of pain after breast cancer therapy despite use of postoperative treatment with conventional analgesics, were invited to participate. A Traumeel and procaine injection was administered once a week for three to 10 sessions. The level of pain was assessed by a pain score and physical and psychological status by a questionnaire before and directly after injection and again at follow-up visits after 3 and 6 months.
RESULTS:
After the last injection, all patients experienced a marked reduction of their level of pain on average from 7.6 +/- 1.5 to 2.4 +/- 1.4 points on a scale from 1 to 10 points. After a followup observational phase of 3 and 6 months, pain score ratings increased slightly again in some patients but remained consistently low in others. In any case, the ratings of pain levels did not reach the values assessed before the start of Traumeel injection. Similarly, health-related quality of life improved with this injection therapy. The perception of pain relief with Traumeel injection was high in 8 of 9 patients, reflecting an overall perceived positive outcome and tolerability of this treatment.
CONCLUSIONS:
This case series represents a first encouraging approach to using this complex homeopathic injection for pain relief in breast cancer patients.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Âðîäå ýôôåêòèâíîñòü äîêàçàíà, íî êðàéíå ìàëà ãðóïïà íàáëþäåíèÿ.
Îáíàðóæèë çàêîíîìåðíîñòü, åñòü ñòàòüè ñ èíòåðåñíûìè è ìíîãîîáåùàþùèìè ðåçóëüòàòàìè, íî èõ íåò â îòêðûòîì äîñòóïå.
Îòâåòèòü ñ öèòèðîâàíèåì
  #14  
Ñòàðûé 17.07.2011, 15:49
Àâàòàð äëÿ Tuu-Tikki
Tuu-Tikki Tuu-Tikki âíå ôîðóìà
Òåðàïåâò äëÿ áåðåìåííûõ
      
 
Ðåãèñòðàöèÿ: 08.02.2006
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 4,804
Ñêàçàë(à) ñïàñèáî: 10
Ïîáëàãîäàðèëè 2,452 ðàç(à) çà 2,214 ñîîáùåíèé
Tuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTuu-Tikki ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Lobanoff Ïîñìîòðåòü ñîîáùåíèå
âïîëíå ïðèåìëåìûé ìåòîä ëå÷åíèÿ, êîãäà ìîæíî îáîéòèñü áåç ëå÷åíèÿ
êîãäà ìîæíî îáîéòèñü áåç ëå÷åíèÿ, ñòîèò îáîéòèñü áåç ëå÷åíèÿ.
__________________
Ñ óâàæåíèåì, Îëüãà Èâàíîâíà Áåëîâåæåö
Îòâåòèòü ñ öèòèðîâàíèåì
  #15  
Ñòàðûé 17.07.2011, 18:22
Àâàòàð äëÿ easl
easl easl âíå ôîðóìà
Âðà÷-èíôåêöèîíèñò
      
 
Ðåãèñòðàöèÿ: 05.02.2008
Ãîðîä: Áàêó
Ñîîáùåíèé: 18,438
Ïîáëàãîäàðèëè 5,211 ðàç(à) çà 4,962 ñîîáùåíèé
easl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Åñëè áóäåò ðåôåðåíäóì ïî ãåëèêîáàêòåðó, áóäó ãîëîñîâàòü çà âêëþ÷åíèå åãî â ãðóïïó ÎÎÈ, è êàê èíôåêöèîíèñòîâ ñ ýòèì ïðîéäîõîé îáîøëè?
Ñïàñèáî îãðîìíîå! Âîò òîëüêî ÷åì ãîìîòîêñèêîëîãèÿ òîãäà êîðìèòüñÿ áóäåò?
Ôèëîñîôèåé è îðãàíèçàöèåé èññëåäîâàíèé, äîêàçûâàþùèõ ýôôåêòèâíîñòü íà óðîâíå ïëàöåáî?
Traumeel S® for pain relief following hallux valgus surgery: a randomized controlled trial
Shepherd R Singer, Michal Amit-Kohn, Samuel Weiss, Jonathan Rosenblum and Guy Maoz, et al.

BMC Clinical Pharmacology, 2010, Volume 10, Number 1, 9

Background
In spite of recent advances in post-operative pain relief, pain following orthopedic surgery remains an ongoing challenge for clinicians. We examined whether a well known and frequently prescribed homeopathic preparation could mitigate post-operative pain.
Method
We performed a randomized, double blind, placebo-controlled trial to evaluate the efficacy of the homeopathic preparation Traumeel S® in minimizing post-operative pain and analgesic consumption following surgical correction of hallux valgus. Eighty consecutive patients were randomized to receive either Traumeel tablets or an indistinguishable placebo, and took primary and rescue oral analgesics as needed. Maximum numerical pain scores at rest and consumption of oral analgesics were recorded on day of surgery and for 13 days following surgery.
Results
Traumeel was not found superior to placebo in minimizing pain or analgesic consumption over the 14 days of the trial, however a transient reduction in the daily maximum post-operative pain score favoring the Traumeel arm was observed on the day of surgery, a finding supported by a treatment-time interaction test (p = 0.04).
Conclusions
Traumeel was not superior to placebo in minimizing pain or analgesic consumption over the 14 days of the trial. A transient reduction in the daily maximum post-operative pain score on the day of surgery is of questionable clinical importance.
Trial Registration
This study was registered at ClinicalTrials.gov. # NCT00279513
__________________
Ñ óâàæåíèåì, Þñèô Àëõàçîâ.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 14:24.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.